+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transforming growth factor beta tgf beta binds to and inhibits estrogen receptor negative but not estrogen receptor positive human breast cancer cells



Transforming growth factor beta tgf beta binds to and inhibits estrogen receptor negative but not estrogen receptor positive human breast cancer cells



Proceedings of the American Association for Cancer Research Annual Meeting 28: 84




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 029471982

Download citation: RISBibTeXText


Related references

Response of estrogen receptor negative and estrogen receptor positive human breast cancer cell lines to tgf beta 1 and tgf beta 2 in anchorage independent growth. Proceedings of the American Association for Cancer Research Annual Meeting 29: 58, 1988

Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Research 48(14): 3898-3904, 1988

Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine. Journal of Biological Chemistry 273(26): 16527-16534, 1998

A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Molecular Biology Reports 35(1): 23-27, 2008

Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Research 53(20): 5004-5011, 1993

Isolation of a heregulin-like growth factor secreted by estrogen receptor-negative MDA-MB-231 human breast cancer cells that stimulates estrogen receptor-positive cells. Biochemical and Biophysical Research Communications 202(3): 1357-1365, 1994

Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clinical Cancer Research 10(2): 491-498, 2004

Transcriptional regulation of transforming growth factor-beta receptor Type II in the estrogen receptor-positive breast cancer cell line, MCF-7. Proceedings of the American Association for Cancer Research Annual Meeting (41): 21, 2000

Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. Steroids 111: 113-120, 2016

Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha. Biochemical and Biophysical Research Communications 463(4): 917-922, 2015

Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Molecular Cancer Therapeutics 8(3): 672-681, 2009

Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Research 63(16): 5005-5010, 2003

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. Journal of Proteomics 94: 279-288, 2013

Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anti-Cancer Drugs 18(7): 835-837, 2007

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial. Cancer 2019:, 2019